RT Journal Article
T1 Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant
A1 Graham, Carl
A1 Seow, Jeffrey
A1 Huettner, Isabella
A1 Khan, Hataf
A1 Kouphou, Neophytos
A1 Acors, Sam
A1 Winstone, Helena
A1 Pickering, Suzanne
A1 Galao, Rui Pedro
A1 Dupont, Liane
A1 Lista, Maria Jose
A1 Jimenez-Guardeño, Jose Manuel
A1 Laing, Adam G
A1 Wu, Yin
A1 Joseph, Magdalene
A1 Muir, Luke
A1 van Gils, Marit J
A1 Ng, Weng M
A1 Duyvesteyn, Helen ME
A1 Zhao, Yuguang
A1 Bowden, Thomas A
A1 Shankar-Hari, Manu
A1 Rosa, Annachiara
A1 Cherepanov, Peter
A1 McCoy, Laura E
A1 Hayday, Adrian C
A1 Neil, Stuart JD
A1 Malim, Michael H.
A1 Doores, Katie J
K1 Virología
AB Interaction of the SARS-CoV-2 Spike receptor binding domain (RBD) with the receptor ACE2 on host cells is essential for viral entry. RBD is the dominant target for neutralizing antibodies, and several neutralizing epitopes on RBD have been molecularly characterized. Analysis of circulating SARS-CoV-2 variants has revealed mutations arising in the RBD, N-terminal domain (NTD) and S2 subunits of Spike. To understand how these mutations affect Spike antigenicity, we isolated and characterized >100 monoclonal antibodies targeting epitopes on RBD, NTD, and S2 from SARS-CoV-2-infected individuals. Approximately 45% showed neutralizing activity, of which ∼20% were NTD specific. NTD-specific antibodies formed two distinct groups: the first was highly potent against infectious virus, whereas the second was less potent and displayed glycan-dependant neutralization activity. Mutations present in B.1.1.7 Spike frequently conferred neutralization resistance to NTD-specific antibodies. This work demonstrates that neutralizing antibodies targeting subdominant epitopes should be considered when investigating antigenic drift in emerging variants.
PB Elsevier
YR 2021
FD 2021
LK https://hdl.handle.net/10630/33870
UL https://hdl.handle.net/10630/33870
LA eng
NO Graham, Carl et al. Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant. Immunity, Volume 54, Issue 6, 1276 - 1289.e6 DOI: 10.1016/j.immuni.2021.03.023
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 15 abr 2026